The Karolinska Institute has awarded the Nobel Prize in Medicine or Physiology to Victor Ambros and Gary Ruvkun for the discovery of microRNAs, small RNA fragments that do not contain instructions for making proteins but instead participate in the regulation of gene expression. Their role is fundamental in processes such as cell differentiation, and their alteration can influence diseases like cancer.

International research in which CREAF is participating estimates that more than 1,300 bird species will disappear over the next two centuries, which is more than double the number of extinctions recorded to date - 610 species have disappeared in the last 130,000 years. The study, published in the journal Science, shows that, for island endemics, the proportional losses have been and will be even greater. The authors warn that when a species becomes extinct, its role in the ecosystem may disappear with it.

If lifetime tobacco consumption were banned among young people currently aged 14 to 18, 1,200,000 lung cancer deaths worldwide could be prevented in the future, according to a study with Spanish involvement published in the journal The Lancet Public Health. The greatest impact would occur in low- and middle-income countries, but in higher-income regions, more than 60% of lung cancer deaths in that age group would also be avoided.

A study published in the journal Frontiers in Aging claims to have developed an epigenetic tool to estimate the risk of death from cells in the mouth.

The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.

The relative risk of being born with a major heart defect is 36% in babies conceived using assisted reproductive techniques, such as in vitro fertilisation, compared to newborns not using these techniques, according to a study published in the European Heart Journal. The absolute risk was 1.84% versus 1.15%. The research, which included more than seven million babies born in Denmark, Finland, Norway and Sweden, also shows that the increased risk is especially associated with multiple births, which are more common in assisted reproduction.
 

Lithium, a material widely used for battery production, is typically extracted from rocks and concentrated brines, but these reserves are expected to run out by 2080. The alternative is to evaporate more diluted brines (such as seawater), but the traditional process is inefficient, polluting, and consumes large amounts of water. Two new studies published in Science propose two more viable and environmentally friendly alternative methods: the first uses a membrane that filters lithium through a transpiration system similar to that of plants, requiring only solar energy. The second combines electrodes to mimic a battery and move lithium from the brine (cathode) to fresh water (anode).

Burying woody biomass in wooden vaults would allow carbon to be extracted and stored from the atmosphere, according to a study published in Science. The authors were inspired by an eastern red cedar log preserved underground for more than 3,700 years in Canada. The team proposes burying wood from sustainable sources in a domed wooden structure designed to extend the duration of carbon storage. The authors estimate that up to 10 gigatonnes of CO₂ could be sequestered annually using this technique.

Prostate cancer screening tests using PSA (Prostate Specific Antigen) are associated with overdiagnosis, which calls into question their use. A clinical trial in men aged 50-60 years published in the journal NEJM has studied the possibility of adding an MRI test in those with an elevated PSA level and dispensing with biopsy if imaging finds no suspicious lesions. The results indicate that the procedure avoids more than half of clinically irrelevant cancer diagnoses that would not need treatment and only slightly increases the risk of failing to identify those that may become incurable. The authors recommend, on the basis of the study, to review the recommendations for such screening.

Rituximab and ocrelizumab are two antibodies with a similar mechanism of action that are used in the treatment of multiple sclerosis. Although the former had not shown benefits in primary progressive multiple sclerosis — which affects between 10% and 15% of patients — the latter is approved for this form of the disease. Now, a study conducted in France with more than 1,000 patients has found no benefits with either treatment, as they did not slow the progression of disability in these individuals. The results are published in the journal Neurology.